论文部分内容阅读
目的 检测乳腺癌及其癌旁组织中的端粒 (TLM )长度、端粒酶 (TLMA )活性的表达 ,探讨乳腺癌端粒长度与端粒酶活性的关系。方法 采用端粒酶重复扩增实验 (TRAP) 银染法检测端粒酶活性 ,以地高辛标记的Southern杂交的方法检测端粒长度。结果 端粒酶活性在乳腺癌TNM分期的进展中由Ⅰ期的 5 9.1%增高到Ⅳ期的 92 .9% ,而端粒长度在乳腺癌TNM分期的进展中不断缩短 ,由Ⅰ期的 (7.5 4± 0 .95 )kb缩短到Ⅳ期的 (5 .0 3± 0 .5 3 )kb。恶性乳腺肿瘤癌旁组织中的平均端粒长度皆位于正常水平。乳腺癌中端粒酶阳性表达组的端粒长度为 (4 .45± 1.3 9)kb显著短于端粒酶阴性组的 (5 .70± 1.2 3 )kb。结论 恶性乳腺肿瘤将端粒酶激活并没有绝对延长其染色体末端的端粒长度 ,而且 ,随着肿瘤的发展端粒片段还会缩短 ,并与端粒酶活性似乎存在着反向的关系。
Objective To detect the expression of telomere length (TLM) and telomerase activity (TLMA) in breast cancer and paracancerous tissues, and to explore the relationship between telomere length and telomerase activity in breast cancer. Methods Telomerase activity was detected by silver staining with telomerase repeat amplification assay (TRAP) and telomere length was detected by Southern blotting with digoxigenin. Results The telomerase activity increased from 51.9% in stage Ⅰ to 92.9% in stage Ⅳ, while telomere length was shortened in the progression of TNM stage in breast cancer. 7.5 4 ± 0.95) kb shortened to (5 .3 ± 0. 53) kb in stage Ⅳ. The average telomere length in paracancerous tissues of malignant breast tumors were all at normal levels. Telomere length was significantly shorter in telomerase positive breast cancer (4.45 ± 1.3 9) kb than in telomerase negative (5.70 ± 1.2 3) kb. CONCLUSIONS: Telomerase activation in malignant breast tumors does not extend telomere length at their chromosomal endpoints, and telomere fragments also shorten as tumors develop, and appear to have an inverse relationship with telomerase activity.